A general process for the development of peptide-based immunoassays for monoclonal antibodies

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 5, 2010, Pages 919-925

  Sanchez, Ana B ^a   Nguyen, Tammy ^a   Dema Ala, Rhanika ^a   Kummel, Andrew C ^a,c   Kipps, Thomas J ^a,b   Messmer, Bradley T ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ELISA; Immunoassay; Monoclonal antibody; Peptide; Phage display

Indexed keywords

ALEMTUZUMAB; PEPTIDE; RITUXIMAB;

AMINO ACID SEQUENCE; ARTICLE; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; PEPTIDE SYNTHESIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROCESS DEVELOPMENT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; PEPTIDE LIBRARY; PEPTIDES;

EID: 77956226977     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1240-1     Document Type: Article

References (25)

1. GP Adams LM Weiner 2005 Monoclonal antibody therapy of cancer Nat Biotechnol 23 1147 1157 10.1038/nbt1137 1:CAS:528:DC%2BD2MXpvVyrtr0%3D 16151408
2. NL Berinstein AJ Grillo-Lopez CA White I Bence-Bruckler D Maloney M Czuczman D Green J Rosenberg P McLaughlin D Shen 1998 Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma Ann Oncol 9 995 1001 10.1023/A:1008416911099 1:STN:280:DyaK1M%2FjsFCgtg%3D%3D 9818074
3. PV Beum AD Kennedy RP Taylor 2004 Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas J Immunol Methods 289 97 109 10.1016/j.jim.2004.03.012 1:CAS:528:DC%2BD2cXlsFOrurY%3D 15251416
4. H Blasco G Lalmanach E Godat MC Maurel S Canepa M Belghazi G Paintaud D Degenne E Chatelut G Cartron C Le Guellec 2007 Evaluation of a peptide ELISA for the detection of rituximab in serum J Immunol Methods 325 127 139 10.1016/j.jim.2007.06.011 1:CAS:528:DC%2BD2sXpt1ShtbY%3D 17651747
5. WL DeLano MH Ultsch AM de Vos JA Wells 2000 Convergent solutions to binding at a protein-protein interface Science 287 1279 1283 10.1126/science.287.5456.1279 1:CAS:528:DC%2BD3cXhtlOqsbg%3D 10678837
6. NL Dirks A Nolting A Kovar B Meibohm 2008 Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck J Clin Pharmacol 48 267 278 10.1177/0091270007313393 1:CAS:528:DC%2BD1cXjs1ekt7w%3D 18218786
7. G Hale 1995 Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein Immunotechnology 1 175 187 10.1016/1380-2933(95)00017-8 1:CAS:528:DyaK28XovFWgsg%3D%3D 9373346
8. G Hale P Rebello LR Brettman C Fegan B Kennedy E Kimby M Leach J Lundin H Mellstedt P Moreton AC Rawstron H Waldmann A Osterborg P Hillmen 2004 Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration Blood 104 948 955 10.1182/blood-2004-02-0593 1:CAS:528: DC%2BD2cXmslKgsrg%3D 15090452
9. HS Hiemstra WE Benckhuijsen R Amons W Rapp JW Drijfhout 1998 A new hybrid resin for stepwise screening of peptide libraries combined with single bead Edman sequencing J Pept Sci 4 282 288 10.1002/(SICI)1099-1387(199806)4:4<282: :AID-PSC145>3.0.CO;2-G 1:CAS:528:DyaK1cXks1Ciu7w%3D 9680061
10. I Jilani M Keating FJ Giles S O'Brien HM Kantarjian M Albitar 2004 Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay Leuk Res 28 1255 1262 10.1016/j.leukres.2004.04.003 1:CAS:528: DC%2BD2cXotlSmtLg%3D 15475065
11. S Leon R Quarrell G Lowe 1998 Evaluation of resins for on-bead screening: a study of papain and chymotrypsin specificity using PEGA-bound combinatorial peptide libraries Bioorg Med Chem Lett 8 2997 3002 10.1016/S0960-894X(98)00534-4 1:CAS:528:DyaK1cXns1Srs7c%3D 9873663
12. FR Luo Z Yang H Dong A Camuso K McGlinchey K Fager C Flefleh D Kan I Inigo S Castaneda WC Rose RA Kramer R Wild FY Lee 2005 Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft Cancer Chemother Pharmacol 56 455 464 10.1007/s00280-005-1022-3 1:CAS:528:DC%2BD2MXhtFGlt7jF 15947929
13. DG Maloney AJ Grillo-Lopez CA White D Bodkin RJ Schilder JA Neidhart N Janakiraman KA Foon TM Liles BK Dallaire K Wey I Royston T Davis R Levy 1997 IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 90 2188 2195 1:CAS:528:DyaK2sXmtVOqsL0%3D 9310469
14. T Manshouri KA Do X Wang FJ Giles SM O'Brien H Saffer D Thomas I Jilani HM Kantarjian MJ Keating M Albitar 2003 Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance Blood 101 2507 2513 10.1182/blood-2002-06-1639 1:CAS:528: DC%2BD3sXivVWgtbg%3D 12446458
15. L Maple R Lathrop S Bozich W Harman R Tacey M Kelley A Danilkovitch-Miagkova 2004 Development and validation of ELISA for herceptin detection in human serum J Immunol Methods 295 169 182 10.1016/j.jim.2004.09.012 1:CAS:528:DC%2BD2MXotVCn 15627622
16. RB Merrifield JM Stewart 1965 Automated peptide synthesis Nature 207 522 523 10.1038/207522a0 1:CAS:528:DyaF2MXkslansL4%3D 5886140
17. BT Messmer JJ Sullivan N Chiorazzi TC Rodman DS Thaler 1999 Two human neonatal igm antibodies encoded by different variable-region genes bind the same linear peptide: evidence for a stereotyped repertoire of epitope recognition J Immunol 162 2184 2192 1:CAS:528:DyaK1MXhtVOmtr0%3D 9973494
18. BT Messmer DS Thaler 2001 Specific blocking to improve biopanning in biological samples such as serum and hybridoma supernatants Biotechniques 30 798 802 1:CAS:528:DC%2BD3MXivVKisrs%3D 11314263
19. M Montagna MA Avanzini L Visai F Locatelli M Montillo E Morra MB Regazzi 2007 A new sensitive enzyme-linked immunosorbent assay (ELISA) for Alemtuzumab determination: development, validation and application Int J Immunopathol Pharmacol 20 363 371 1:CAS:528:DC%2BD2sXptFGlurY%3D 17624249
20. F Perosa E Favoino C Vicenti F Merchionne F Dammacco 2007 Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy J Immunol 179 7967 7974 1:CAS:528:DC%2BD2sXhtlajt7bK 18025245
21. Rapp W, Zhang L, Bayer E (1989) Continuous-flow peptide synthesis on PSPOE-grafi-copolymers. In: Epton R (ed) Innovations and perspectives in solid-phase synthesis. Oxford, Mayflower, Birmingham. pp 205-210
22. P Rebello G Hale 2002 Pharmacokinetics of CAMPATH-1H: assay development and validation J Immunol Methods 260 285 302 10.1016/S0022-1759(01)00556-7 1:CAS:528:DC%2BD38XktFagtg%3D%3D 11792397
23. N Sachdeva D Asthana 2007 Cytokine quantitation: technologies and applications Front Biosci 12 4682 4695 10.2741/2418 1:CAS:528: DC%2BD2sXms1Klt7k%3D 17485405
24. AR Tan DF Moore M Hidalgo JH Doroshow EA Poplin S Goodin D Mauro EH Rubin 2006 Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors Clin Cancer Res 12 6517 6522 10.1158/1078-0432.CCR-06-0705 1:CAS:528:DC%2BD28XhtFKitbvN 17065274
25. ME Williams JJ Densmore AW Pawluczkowycz PV Beum AD Kennedy MA Lindorfer SH Hamil JC Eggleton RP Taylor 2006 Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia J Immunol 177 7435 7443 1:CAS:528:DC%2BD28XhtFGrtrfI 17082663